Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
OBJECTIVE
The incretins glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal peptide hormones regulating postprandial insulin release from pancreatic β-cells. GLP-1 agonism is a treatment strategy in Type 2 diabetes and is evaluated in Non-alcoholic fatty liver disease (NAFLD). However, the role of incretins in its pathophysiology is insufficiently understood. Studies in mice suggest improvement of hepatic steatosis by GLP-1 agonism. We determined the secretion of incretins after oral glucose administration in non-diabetic NAFLD patients.


METHODS
N=52 patients (n=16 NAFLD and n=36 Non-alcoholic steatohepatitis (NASH) patients) and n=50 matched healthy controls were included. Standardized oral glucose tolerance test was performed. Glucose, insulin, glucagon, GLP-1 and GIP plasma levels were measured sequentially for 120 minutes after glucose administration.


RESULTS
Glucose induced GLP-1 secretion was significantly decreased in patients compared to controls (p<0.001). In contrast, GIP secretion was unchanged. There was no difference in GLP-1 and GIP secretion between NAFLD and NASH subgroups. All patients were insulin resistant, however HOMA2-IR was highest in the NASH subgroup. Fasting and glucose-induced insulin secretion was higher in NAFLD and NASH compared to controls, while the glucose lowering effect was diminished. Concomitantly, fasting glucagon secretion was significantly elevated in NAFLD and NASH.


CONCLUSIONS
Glucose-induced GLP-1 secretion is deficient in patients with NAFLD and NASH. GIP secretion is contrarily preserved. Insulin resistance, with hyperinsulinemia and hyperglucagonemia, is present in all patients, and is more severe in NASH compared to NAFLD. These pathophysiologic findings endorse the current evaluation of GLP-1 agonism for the treatment of NAFLD.
Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland ; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Christine
C
Bernsmeier
Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Anne C
AC
Meyer-Gerspach
Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Lea S
LS
Blaser
Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Lia
L
Jeker
Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Robert E
RE
Steinert
Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland ; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Markus H
MH
Heim
Division of Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland ; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Christoph
C
Beglinger
D016022:Case-Control Studies; D005234:Fatty Liver / Q000097:blood*; D005260:Female; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000097:blood / Q000378:metabolism*; D005947:Glucose / Q000502:physiology*; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease
D007328:Insulin; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose